Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Payables (2016 - 2025)

Historic Payables for CytomX Therapeutics (CTMX) over the last 12 years, with Q3 2025 value amounting to $646000.0.

  • CytomX Therapeutics' Payables fell 5457.1% to $646000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $646000.0, marking a year-over-year decrease of 5457.1%. This contributed to the annual value of $1.1 million for FY2024, which is 2537.72% down from last year.
  • Latest data reveals that CytomX Therapeutics reported Payables of $646000.0 as of Q3 2025, which was down 5457.1% from $227000.0 recorded in Q2 2025.
  • In the past 5 years, CytomX Therapeutics' Payables ranged from a high of $5.2 million in Q3 2022 and a low of $227000.0 during Q2 2025
  • Moreover, its 5-year median value for Payables was $1.7 million (2023), whereas its average is $1.7 million.
  • In the last 5 years, CytomX Therapeutics' Payables soared by 24142.48% in 2022 and then tumbled by 8594.7% in 2025.
  • Over the past 5 years, CytomX Therapeutics' Payables (Quarter) stood at $2.8 million in 2021, then dropped by 0.32% to $2.8 million in 2022, then plummeted by 48.1% to $1.5 million in 2023, then decreased by 25.38% to $1.1 million in 2024, then tumbled by 40.62% to $646000.0 in 2025.
  • Its last three reported values are $646000.0 in Q3 2025, $227000.0 for Q2 2025, and $276000.0 during Q1 2025.